将扎那米韦连接到聚合物上显著增强了其对流感 a 病毒耐药株的活性。
Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus.
机构信息
Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.
出版信息
J Pharm Sci. 2011 Mar;100(3):831-5. doi: 10.1002/jps.22338. Epub 2010 Aug 25.
Abstract
Effects of the commercial drug zanamivir (Relenza) covalently attached to poly-l-glutamine on the infectivity of influenza A viruses are examined using the plaque reduction assay and binding affinity to viral neuraminidase (NA). These multivalent drug conjugates exhibit (i) up to a 20,000-fold improvement in anti-influenza potency compared with the zanamivir parent against human and avian viral strains, including both wild-type and drug-resistant mutants, and (ii) superior neuraminidase (NA) inhibition constants, especially for the mutants. These findings provide a basis for exploring polymer-attached inhibitors as more efficacious therapeutics, particularly against drug-resistant influenza strains.
摘要
研究了共价连接到聚-L-谷氨酰胺上的商业药物扎那米韦（瑞乐沙）对流感 A 病毒感染力的影响，使用噬斑减少测定法和与病毒神经氨酸酶（NA）的结合亲和力来检测。这些多价药物缀合物表现出（i）与扎那米韦母体相比，对人类和禽源病毒株（包括野生型和耐药突变体）的抗流感效力提高了多达 20,000 倍，（ii）对神经氨酸酶（NA）的抑制常数更高，尤其是对突变体。这些发现为探索聚合物连接抑制剂作为更有效的治疗药物提供了依据，特别是针对耐药性流感株。
相似文献
1
Attaching zanamivir to a polymer markedly enhances its activity against drug-resistant strains of influenza a virus.
J Pharm Sci. 2011 Mar;100(3):831-5. doi: 10.1002/jps.22338. Epub 2010 Aug 25.
2
Neuraminidase inhibitor susceptibility of swine influenza A viruses isolated in Germany between 1981 and 2008.
Med Microbiol Immunol. 2012 Feb;201(1):61-72. doi: 10.1007/s00430-011-0206-1. Epub 2011 Jun 19.
3
Resistance to Mutant Group 2 Influenza Virus Neuraminidases of an Oseltamivir-Zanamivir Hybrid Inhibitor.
J Virol. 2016 Nov 14;90(23):10693-10700. doi: 10.1128/JVI.01703-16. Print 2016 Dec 1.
4
Hydrophobic polycationic coatings inactivate wild-type and zanamivir- and/or oseltamivir-resistant human and avian influenza viruses.
Biotechnol Lett. 2008 Mar;30(3):475-9. doi: 10.1007/s10529-007-9565-5. Epub 2007 Oct 31.
5
Comprehensive assessment of 2009 pandemic influenza A (H1N1) virus drug susceptibility in vitro.
Antivir Ther. 2010;15(8):1151-9. doi: 10.3851/IMP1678.
6
A surface plasmon resonance assay for measurement of neuraminidase inhibition, sensitivity of wild-type influenza neuraminidase and its H274Y mutant to the antiviral drugs zanamivir and oseltamivir.
J Mol Recognit. 2015 Sep;28(9):521-7. doi: 10.1002/jmr.2467. Epub 2015 Mar 2.
7
Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.
Clin Diagn Lab Immunol. 2004 Jan;11(1):21-8. doi: 10.1128/cdli.11.1.21-28.2004.
8
Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.
mBio. 2013 Jul 16;4(4):e00396-13. doi: 10.1128/mBio.00396-13.
9
In vitro selection and characterization of influenza A (A/N9) virus variants resistant to a novel neuraminidase inhibitor, A-315675.
J Virol. 2002 Jun;76(11):5380-6. doi: 10.1128/jvi.76.11.5380-5386.2002.
10
A single E105K mutation far from the active site of influenza B virus neuraminidase contributes to reduced susceptibility to multiple neuraminidase-inhibitor drugs.
Biochem Biophys Res Commun. 2012 Dec 7;429(1-2):51-6. doi: 10.1016/j.bbrc.2012.10.095. Epub 2012 Nov 3.
引用本文的文献
1
Sialic acids in infection and their potential use in detection and protection against pathogens.
RSC Chem Biol. 2023 Dec 19;5(3):167-188. doi: 10.1039/d3cb00155e. eCollection 2024 Mar 6.
2
Multiscale Simulations Examining Glycan Shield Effects on Drug Binding to Influenza Neuraminidase.
Biophys J. 2020 Dec 1;119(11):2275-2289. doi: 10.1016/j.bpj.2020.10.024. Epub 2020 Oct 31.
3
Five Novel Non-Sialic Acid-Like Scaffolds Inhibit In Vitro H1N1 and H5N2 Neuraminidase Activity of Influenza a Virus.
Molecules. 2020 Sep 16;25(18):4248. doi: 10.3390/molecules25184248.
4
Antivirals Targeting the Neuraminidase.
Cold Spring Harb Perspect Med. 2022 Jan 4;12(1):a038455. doi: 10.1101/cshperspect.a038455.
5
Development of effective anti-influenza drugs: congeners and conjugates - a review.
J Biomed Sci. 2019 Oct 23;26(1):84. doi: 10.1186/s12929-019-0567-0.
6
Human Influenza Virus Infections.
Semin Respir Crit Care Med. 2016 Aug;37(4):487-500. doi: 10.1055/s-0036-1584801. Epub 2016 Aug 3.
7
8
Antiviral strategies against influenza virus: towards new therapeutic approaches.
Cell Mol Life Sci. 2014 Oct;71(19):3659-83. doi: 10.1007/s00018-014-1615-2. Epub 2014 Apr 4.
9
Zanamivir conjugated to poly-L-glutamine is much more active against influenza viruses in mice and ferrets than the drug itself.
Pharm Res. 2014 Feb;31(2):466-74. doi: 10.1007/s11095-013-1175-4. Epub 2013 Sep 25.
10
Conjugation to polymeric chains of influenza drugs targeting M2 ion channels partially restores inhibition of drug-resistant mutants.
J Pharm Sci. 2013 Aug;102(8):2450-9. doi: 10.1002/jps.23644. Epub 2013 Jul 6.
本文引用的文献
1
Polyvalent Interactions in Biological Systems: Implications for Design and Use of Multivalent Ligands and Inhibitors.
Angew Chem Int Ed Engl. 1998 Nov 2;37(20):2754-2794. doi: 10.1002/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3.
2
Bifunctional polymeric inhibitors of human influenza A viruses.
Pharm Res. 2010 Feb;27(2):259-63. doi: 10.1007/s11095-009-0013-1. Epub 2009 Dec 15.
3
CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.
Antimicrob Agents Chemother. 2009 Nov;53(11):4845-51. doi: 10.1128/AAC.00731-09. Epub 2009 Aug 17.
4
CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.
Antimicrob Agents Chemother. 2009 Jan;53(1):186-92. doi: 10.1128/AAC.00333-08. Epub 2008 Oct 27.
5
Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant.
J Chem Inf Model. 2008 Oct;48(10):2074-80. doi: 10.1021/ci800242z. Epub 2008 Oct 11.
6
Oseltamivir resistance--disabling our influenza defenses.
N Engl J Med. 2005 Dec 22;353(25):2633-6. doi: 10.1056/NEJMp058291.
7
Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.
Antimicrob Agents Chemother. 2005 Nov;49(11):4515-20. doi: 10.1128/AAC.49.11.4515-4520.2005.
8
Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen.
Antimicrob Agents Chemother. 2004 Dec;48(12):4542-9. doi: 10.1128/AAC.48.12.4542-4549.2004.
9
Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium.
J Virol. 2004 Nov;78(22):12665-7. doi: 10.1128/JVI.78.22.12665-12667.2004.
10
Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.
J Infect Dis. 2004 Nov 1;190(9):1627-30. doi: 10.1086/424572. Epub 2004 Sep 28.
Zotero 插件